CN104069192B - A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof - Google Patents
A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof Download PDFInfo
- Publication number
- CN104069192B CN104069192B CN201310100487.6A CN201310100487A CN104069192B CN 104069192 B CN104069192 B CN 104069192B CN 201310100487 A CN201310100487 A CN 201310100487A CN 104069192 B CN104069192 B CN 104069192B
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma rhei
- chinese medicine
- tabanus
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof. The traditional Chinese medicine composition mainly comprises following raw material medicines: rheum officinale and gadfly. The preparing method includes: weighing the raw material medicines according to a ratio, and extracting with water or an organic solvent mutually soluble with water; or weighing the raw material medicines according to the ratio and preparing by adoption of a water extraction and alcohol precipitation method, wherein the alcohol precipitation concentration is 50-90%. The uses of the composition relate to applications of the composition in preparation of medicines treating cancer especially medicines treating cervical cancer. The composition comprises the rheum officinale and the gadfly in a weight ratio of 1:0.2-4. By compatibility of the rheum officinale and the gadfly, the composition has coordinate repression effects for Hela cells and has good anticancer effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and its production and use, and in particular to a kind of with antitumaous effect
Chinese medicine composition and its production and use, belongs to technical field of Chinese medicine.
Background technology
Cancer is the major disease for jeopardizing human health, and its fatality rate is in the trend for rising year by year, its occurrence and development
It is the complex lesions process of multifactor participation, polygenes change and Multi stage development.At present for the treatment of cancer is adopted mostly
Operative treatment combines Radiotherapy chemotherapy method, but the method is big to the wound of patient, dangerous high, and somewhat expensive, but curative effect
It is unsatisfactory.The weapon that Chinese medicine is prevented and cured diseases as China's tradition, along with progressively in-depth study and exploration in recent years, in cancer
Increasingly it is taken seriously in disease treatment.Research shows, during treatment and prevention of tumour, Chinese medicine is mainly from raising immunity of organism work(
Energy, inducing apoptosis of tumour cell, the suppression aspect such as Nasopharyngeal neoplasms and the attenuation synergistic to chemotherapy play a role.
Chinese medicine composition compatibility of the present invention rationally, can adjust negative and positive of qi and blood and function, protect bone marrow hematogenesis
Function, can start self-defensive system again, improve immunity of organisms, very helpful for the auxiliary treatment of tumor.
The content of the invention
First purpose of the present invention is to provide a kind of Chinese medicine composition with antitumaous effect.
Second object of the present invention is the preparation method for providing said composition.
Third object of the present invention is the application for providing said composition in treating cancer medicine is prepared.
Fourth object of the present invention is the application for providing said composition in treatment cervix uteri cancer drug is prepared.
The purpose of the present invention is achieved by the following technical solution：
A kind of Chinese medicine composition with antitumaous effect, the Chinese medicine composition are made up of the crude drug of following weight ratio：
Radix Et Rhizoma Rhei：Tabanus=1：（0.2-4）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei：Tabanus=1：（0.3-3.5）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei：Tabanus=1：（0.4-3）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei：Tabanus=1：（0.5-2.5）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei：Tabanus=1：（0.5-2.2）.
The crude drug of the Chinese medicine composition is preferably：
The Radix Paeoniae Alba：Radix Angelicae Sinensis=1：（0.5-2）.
The crude drug of the Chinese medicine composition is more preferably：
Radix Et Rhizoma Rhei：Tabanus=1：0.5；
Or, Radix Et Rhizoma Rhei：Tabanus=1：1；
Or, Radix Et Rhizoma Rhei：Tabanus=1：2.
Chinese medicine composition of the present invention can be prepared as follows：
Crude drug is taken in proportion, the organic solvent extraction mutually dissolved each other with water or with water；
Further, one or more being selected from the organic solvent that water mutually dissolves each other in methanol, ethanol, acetone；More
The more preferably ethanol of 50-90%；It is still more preferably the ethanol of 60-80%；Ethanol still more preferably for 70%；
Extracting method used includes decocting appointing in extraction, reflux, extract, soak extraction, supersound extraction or seepage pressure effects
Anticipate a kind of mode, or the combination of Different Extraction Method.
Chinese medicine composition of the present invention can also be adopted：Crude drug is taken in proportion, is prepared using decoction and alcohol sedimentation technique；Wherein described alcohol
Heavy concentration is 50-90%；
Further, the alcohol precipitation concentration is 60-80%；Further described alcohol precipitation concentration is 70%.
Can also be purified, refined after in above-mentioned preparation method, crude drug is extracted, such as cross macroporous resin column；And further press
Conventional preparation process makes the acceptable any conventional formulation of pharmaceuticss, including granule, tablet, capsule, drop pill, oral liquid,
Suspension, emulsion, injection.
To enable above-mentioned dosage form to realize, pharmaceutically acceptable adjuvant need to be added when these dosage forms are prepared, for example：Filling
Agent, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctivess, preservative, substrate etc..Filler includes：It is starch, pre-
Gelling starch, Lactose, Mannitol, chitin, Microcrystalline Cellulose, sucrose etc.；Disintegrating agent includes：It is starch, pregelatinized Starch, micro-
Crystalline cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, Croscarmellose Sodium
Deng；Lubricant includes：Magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.；Suspending agent includes：Polyvinyl pyrrole
Alkanone, Microcrystalline Cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Binding agent includes：Starch slurry, polyvinylpyrrolidine
Ketone, hydroxypropyl methyl cellulose etc.；Sweeting agent includes：Saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.；Taste masking
Agent includes：Sweeting agent and various essence；Preservative includes：Parabenses, benzoic acid, sodium benzoate, sorbic acid and its esters, benzene
Prick fixed, eucalyptus oil of bromine ammonium, acetic acid chloroethene etc.；Substrate includes：PEG6000, PEG4000, insect wax etc..To enable above-mentioned dosage form real
Existing pharmacy of Chinese materia medica, need to add pharmaceutically acceptable other adjuvants when these dosage forms are prepared（Fan Biting《Pharmacy of Chinese materia medica》, on
The adjuvant that each dosage form is recorded in extra large Science Press December in 1997 the 1st edition）.
In addition to Chinese medicine composition of the present invention is in the form of fed intake with Radix Et Rhizoma Rhei, Tabanus crude drug, can also adopt with big
Yellow, Tabanus extract（Effective site）The form for feeding intake, thus it is the present invention further discloses a kind of with antitumaous effect
Drug composition：
A kind of Chinese medicine composition with antitumaous effect, the Chinese medicine composition are made up of the raw material of following weight ratio：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.2-4）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.3-3.5）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.4-3）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.5-2.5）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.5-2.2）.
The crude drug of the Chinese medicine composition is preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：（0.5-2）.
The crude drug of the Chinese medicine composition is more preferably：
Radix Et Rhizoma Rhei extract：Tabanus extract=1：0.5；
Or, Radix Et Rhizoma Rhei extract：Tabanus extract=1：1；
Or, Radix Et Rhizoma Rhei extract：Tabanus extract=1：2.
Radix Et Rhizoma Rhei extract of the present invention and Tabanus extract are respectively Radix Et Rhizoma Rhei, the water extract of Tabanus or are mutually dissolved each other with water
Extractive with organic solvent；Or, the extract that respectively Radix Et Rhizoma Rhei, Tabanus are obtained Jing after water extract-alcohol precipitation process.
Further, one or more being selected from the organic solvent that water mutually dissolves each other in methanol, ethanol, acetone；More
The more preferably ethanol of 50-90%；It is still more preferably the ethanol of 60-80%；Ethanol still more preferably for 70%；
Extracting method used includes decocting appointing in extraction, reflux, extract, soak extraction, supersound extraction or seepage pressure effects
Anticipate a kind of mode, or the combination of Different Extraction Method.
Further, the alcohol precipitation concentration is 50-90%；Further preferably alcohol precipitation concentration is 60-80%；Further institute
Alcohol precipitation concentration is stated for 70%.
Decoction and alcohol sedimentation technique of the present invention means that in Chinese medicine water extracting liquid addition ethanol makes to reach the alcohol content of regulation
（That is alcohol precipitation concentration）, some compositions dissolubility reduction precipitation precipitation, filtration in alcoholic solution take ethanol solution, reclaim ethanol and obtain
Extract, makes Aqueous extracts be able to refined method.
Test result indicate that, Radix Et Rhizoma Rhei plays coordinate repression CI with Tabanus compatibility to human cervical carcinoma Hela cell<1(0.1<
Fa<0.9)。
The research of 1 Elsholtzia pair of experimental example
1 material
Human cervical carcinoma Hela cell is given by central laboratory of Tianjin Cancer Institute；RPMI-1640 culture medium, the U.S.
GIBCO Products；
The each single medicine of Radix Et Rhizoma Rhei, Semen Persicae, Hirudo, Tabanus and Radix Et Rhizoma Rhei respectively at Semen Persicae, Hirudo, Tabanus compatibility compositionss（As
" medicine to "）Adopt and prepare with the following method：Crude drug is taken, 30min is soaked, adds 8 times of amount decoctings to boil three times, every time 1.5
Hour, filtration, merging filtrate are centrifuged, dry, pulverize into powder.Empirically need to be made into xeraphium DMEM high glucose mediums
The reagent filtration sterilization of respective concentration.
2 experimental techniques
Hela cell is in 5%CO2Cultivate in incubator, culture medium is the RPMI-l640 containing 10% inactivation calf serum,
Containing 1% dual anti-(penicillin and streptomycin).Passed on once per 2～3 days, trophophase cell of taking the logarithm is used to test.24 orifice plates are every
Hole is inoculated with 5000/m1 Hela cell, and dosing culture in 24 hours after inoculation, selection have obvious inhibiting effect to Hela cells propagation
Radix Et Rhizoma Rhei, by its with other drugs compatibility using Hela cells are acted on, be equipped with alone group of Radix Et Rhizoma Rhei, Tabanus, Semen Persicae, Hirudo and big
Yellow and Tabanus compatibility combination group（By 1:2 ratios）, Radix Et Rhizoma Rhei and Semen Persicae compatibility combination group（By 1:2 ratios）, Radix Et Rhizoma Rhei and Hirudo compatibility
Combination group（By 1:2 ratios）.Drug level is added with different pharmaceutical compatibility middle dose group In vitro culture with following formula conversion Radix Et Rhizoma Rhei：C(μ
g/mL)=5D(mg/Kg/d)；C is experiment in vitro desired concn, and D is clinical application concentration.With this concentration as intermediate concentration, respectively
Upwards, downward 2 times are successively decreased, and continuously arrange 6 Concentraton gradient.96h, light Jing Microscopic observation each group cell shapes are cultivated in incubator
State changes, and collects cell afterwards, and row trypan blue is counted.
Joint drug effect is judged with median-effect principle：Middle effect concentration（Dm）, i.e. half-inhibition concentration (IC50) calculating, according to
Trypan blue exclusion viable count calculates medicine group cell fu（Survival rate fraction of unaffeeted cells）And fa（Suppression
Rate fraetion of affected cells processed）
The average viable count of the average viable count/matched group of fu=test groups
fa=1-fu
Middle efficacious prescriptions journey fa/fu=(D/Dm) m both sides are taken the logarithm（D is drug level；Dm is middle effect concentration）Obtain equation:
log(fa/fu)=mLogD-mLogDm
So as to Dx=Dm × [fa/ (l-fa)]l/m
If Y=log (fa/fu), X=logD, then linear equation is obtained:
Y=mX+a（The slope of m equations, a are equation intercept）
During Fa=0.5, X=logDm=-a/m calculates Dm values when alone medicine and use in conjunction
Calculate and reach various effect (fa=0.1,0.2,0.3 ... using this formula Dx=Dm × [fa/ (1-fa)] 1//m
0.9) when, two kinds of medicines are alone and use in conjunction required for drug level (D)
CI (The Combination when two medicines are shared are calculated according to the amount in week-Te Shi association index method-effect formula
Index) value
Clx=D1/Dxl+D2/Dx2
Note：Dl in formula, D2 are for, when sharing, concentration shared by two medicines when effect reaches X, Dxl, Dx2 were two prescription used times, were imitated
Should be up to respective concentration during X.Factor alpha is imitated mapping according in and is determined, when the mapping of two medicines is parallel to each other, α values are 0, otherwise is 1.
Result judgement：CI<Collaboration (synergism) effect is produced when l represents that two medicines are shared；When CI=1 represents that two medicines are shared
Produce and be added (additivity) effect；CI>Antagonism (antagonism) effect is produced when l represents that two medicines are shared.
Middle effect concentration and joint drug effect pass through CalcuSyn computed in software and are fitted chart.
3 statistical method
Using SPSS16.0 statistics analysis software packages, experimental data is with mean ± standard deviation（）Represent, in check number
Under conditions of according to normal distribution and homogeneity of variance, multigroup data compare and adopt variance analyses, and the comparison of each group group difference is used
LSD-t is checked.With P ＜ 0.05 as statistically significant.
4 experimental results
The impact that 4.1 Radix Et Rhizoma Rhei are bred to Hela cells with Tabanus compatibility
Trypan blue counting method detects different experiments group：Radix Et Rhizoma Rhei and Tabanus are alone and share（By 1:2 ratio compatibilities）For people
Viable count after s strain 96h, calculates the Fa under each concentration of each experimental group.Using Excel and CalcuSyn
Computed in software Radix Et Rhizoma Rhei, the IC50 of Tabanus are respectively 56.18 μ g/mL, 241.108 μ g/mL.Calculate Radix Et Rhizoma Rhei and Tabanus is shared in difference
CI values during effect to Hela cells, statistical analysiss show that Radix Et Rhizoma Rhei plays coordinate repression CI to Hela cells with Tabanus compatibility<
1(0.1<Fa<0.9)（Refer to table 1- tables 2）.
1 variable concentrations Radix Et Rhizoma Rhei of table and Tabanus are alone and share effect Fa cytostatic to Hela
2 Radix Et Rhizoma Rhei of table and CI index of the Tabanus compatibility to Hela cell growths
| Dosage (μ g/ml) | CI |
| 250+500 | 0.761 |
| 125+250 | 0.683 |
| 62.5+125 | 0.687 |
| 31.25+62.5 | 0.691 |
| 15.625+31.25 | 0.693 |
| 7.8125+15.625 | 0.696 |
The impact that 4.2 Radix Et Rhizoma Rhei are bred to Hela cells with Semen Persicae compatibility
The joint in different effect to Hela cells is shared using Excel and CalcuSyn computed in software Radix Et Rhizoma Rhei and Semen Persicae
Exponential quantity（CI）Statistical analysiss show, Radix Et Rhizoma Rhei and Semen Persicae compatibility are 0.1<Fa<Antagonism is played to the Proliferation Ability of Hela cells when 0.9
Effect (CI>1)（Refer to table 3- tables 4）.
3 variable concentrations Radix Et Rhizoma Rhei of table and Semen Persicae are alone and share effect Fa cytostatic to Hela
4 Radix Et Rhizoma Rhei of table and CI index of the Semen Persicae compatibility to Hela cell growths
| Dosage (μ g/ml) | CI |
| 250+500 | 1.875 |
| 125+250 | 1.369 |
| 62.5+125 | 1.132 |
| 31.25+62.5 | 1.543 |
| 15.625+31.25 | 1.293 |
| 7.8125+15.625 | 2.263 |
The impact that 4.3 Radix Et Rhizoma Rhei are bred to Hela cells with Hirudo compatibility
Show using each combination group CI of CalcuSyn computed in software：Radix Et Rhizoma Rhei presses down to Hela cells antagonism with during Hirudo compatibility
Make and use (CI>1)（Refer to table 5- tables 6）.
5 variable concentrations Radix Et Rhizoma Rhei of table and Hirudo are alone and share effect Fa cytostatic to Hela
6 Radix Et Rhizoma Rhei of table and CI index of the Hirudo compatibility to Hela cell growths
| Dosage (μ g/ml) | CI |
| 250+500 | 2.402 |
| 125+250 | 1.577 |
| 62.5+125 | 1.281 |
| 31.25+62.5 | 1.561 |
| 15.625+31.25 | 11.179 |
| 7.8125+15.625 | 62.820 |
The research of 2 Radix Paeoniae Alba pair of experimental example
1 material
Human cervical carcinoma Hela cell is given by central laboratory of Tianjin Cancer Institute；RPMI-1640 culture medium, the U.S.
GIBCO Products；
The each single medicine of the Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae Preparata and the Radix Paeoniae Alba are adopted by the compositionss of different proportion compatibility respectively at Rhizoma Chuanxiong, Radix Rehmanniae Preparata
It is prepared by following method：Crude drug is taken, 30min is soaked, adds 8 times of amount decoctings to boil three times, 1.5 hours every time, filtration merged
Filtrate, is centrifuged, dry, pulverize into powder.Empirically need xeraphium DMEM high glucose mediums are made into the reagent of respective concentration
And filtration sterilization.
2 experimental techniques
Take the logarithm the Hela cells of trophophase, pancreatin digests and blows and beats as cell suspension.Cell is collected by centrifugation, is adjusted after counting
The cell concentration of whole suspension is 1 × 104/ mL, is inoculated in 24 porocyte culture plates, chooses right according to 2.1 experimental results per hole 1mL
Hela cells propagation has the Radix Paeoniae Alba of obvious inhibiting effect, and itself and other drugs are pressed different proportion variable concentrations compatibility using effect
In Hela cells, the Radix Paeoniae Alba and Radix Rehmanniae Preparata are equipped with by 1:1、2:1、1：2 ratio compatibility combination groups, the Radix Paeoniae Alba and Rhizoma Chuanxiong press 1:1、2:1、1：2
Ratio compatibility combination group, and negative control group.Added with different pharmaceutical compatibility middle dose group In vitro culture with the following formula conversion Radix Paeoniae Alba
Drug level：C(μg/mL)=5D(mg/Kg/d)；C is experiment in vitro desired concn, and D is clinical application concentration.With this concentration it is
Intermediate concentration, respectively upwards, downward 2 times successively decrease, 6 Concentraton gradient are continuously set.96h is cultivated in incubator, under light Jing mirrors
The cellular morphology change of observation each group, collects cell afterwards, and row trypan blue is counted.
Joint drug effect is judged with median-effect principle：Middle effect concentration（Dm）, i.e. half-inhibition concentration (IC50) calculating, according to
Trypan blue exclusion viable count calculates medicine group cell fu（Survival rate fraction of unaffeeted cells）And fa（Suppression
Rate fraetion of affected cells processed）
The average viable count of the average viable count/matched group of fu=test groups
fa=1-fu
Middle efficacious prescriptions journey fa/fu=(D/Dm) m both sides are taken the logarithm（D is drug level；Dm is middle effect concentration）Obtain equation:
log(fa/fu)=mLogD-mLogDm
So as to Dx=Dm × [fa/ (l-fa)]l/m
If Y=log (fa/fu), X=logD, then linear equation is obtained:
Y=mX+a（The slope of m equations, a are equation intercept）
During Fa=0.5, X=logDm=-a/m calculates Dm values when alone medicine and use in conjunction
Calculate and reach various effect (fa=0.1,0.2,0.3 ... using this formula Dx=Dm × [fa/ (1-fa)] 1//m
0.9) when, two kinds of medicines are alone and use in conjunction required for drug level (D)
CI (The Combination when two medicines are shared are calculated according to the amount in week-Te Shi association index method-effect formula
Index) value
Clx=D1/Dxl+D2/Dx2
Note：Dl in formula, D2 are for, when sharing, concentration shared by two medicines when effect reaches X, Dxl, Dx2 were two prescription used times, were imitated
Should be up to respective concentration during X.Factor alpha is imitated mapping according in and is determined, when the mapping of two medicines is parallel to each other, α values are 0, otherwise is 1.
Result judgement：CI<Collaboration (synergism) effect is produced when l represents that two medicines are shared；When CI=1 represents that two medicines are shared
Produce and be added (additivity) effect；CI>Antagonism (antagonism) effect is produced when l represents that two medicines are shared.
Middle effect concentration and joint drug effect pass through CalcuSyn computed in software and are fitted chart.
3 statistical method
Using SPSS16.0 statistics analysis software packages, experimental data is with mean ± standard deviation（）Represent, in check number
Under conditions of according to normal distribution and homogeneity of variance, multigroup data compare and adopt variance analyses, and the comparison of each group group difference is used
LSD-t is checked.With P ＜ 0.05 as statistically significant.
4 experimental results
The impact that 4.1 Radix Paeoniae Albas are bred to Hela cells with Radix Rehmanniae Preparata compatibility
Trypan blue counting method detects different experiments group：The Radix Paeoniae Alba and Radix Rehmanniae Preparata press 1:1,1:2 and 2:1 compatibility is shared in human cervical carcinoma
Viable count after Hela cell strain 96h, calculates the cell inhibitory rate under each concentration of each experimental group.Using Excel and
The CalcuSyn computed in software Radix Paeoniae Alba and Radix Rehmanniae Preparata share the association index value in different effect to Hela cells（CI）Statistical analysiss
Show, the Radix Paeoniae Alba presses different proportion compatibility 0.1 with Radix Rehmanniae Preparata<Fa<Antagonism (CI is played to the Proliferation Ability of Hela cells when 0.9>
1), wherein synergism CI=0.983 (0.1 slight from only as 125 μ g/mL+ 62.5 μ g/mL of Radix Rehmanniae Preparata of the Radix Paeoniae Alba<Fa<0.9)
（Refer to table 7- tables 9）.
The 7 variable concentrations Radix Paeoniae Alba of table and Radix Rehmanniae Preparata are alone to cytostatic effects Fa of Hela
8 Radix Paeoniae Alba of table and Radix Rehmanniae Preparata share effect Fa cytostatic to Hela
9 Radix Paeoniae Alba of table and CI index of the Radix Rehmanniae Preparata different proportion compatibility to Hela cell growths
The impact that 4.2 Radix Paeoniae Albas are bred to Hela cells with Rhizoma Chuanxiong compatibility
Trypan exclusion stain detection different experiments group acts on the viable count after Hela cell 96h, calculates Carbazole alkaloid
Rate.Show using each combination group CI of CalcuSyn computed in software：The Radix Paeoniae Alba presses 1 with Rhizoma Chuanxiong:1,2:To Hela cells during 1 ratio compatibility
Play antagonism inhibitory action (CI>1).The Radix Paeoniae Alba and Rhizoma Chuanxiong 1:It is during 2 compatibility, only slight as 125 μ g/mL+ 250 μ g/mL of Rhizoma Chuanxiong of the Radix Paeoniae Alba
Synergism, CI=0.96 (0.1<Fa<0.9) it is, remaining to be antagonistic effect (CI>1)（Refer to table 10- tables 12）.
The 10 variable concentrations Radix Paeoniae Alba of table and Rhizoma Chuanxiong are alone to cytostatic effects Fa of Hela
11 Radix Paeoniae Alba of table and Rhizoma Chuanxiong share effect Fa cytostatic to Hela
12 Radix Paeoniae Alba of table and CI index of the Rhizoma Chuanxiong different proportion compatibility to Hela cell growths
Specific embodiment
1 oral liquid of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 30g；
The crude drug of recipe quantity is taken, is added water to cook 2 times, 2 hours for the first time, second 1.5 hours, collecting decoction, filtration,
Filtrate concentrates, and concentrated solution adds ethanol to alcohol content to 70%, stands, filtration, and filtrate recycling ethanol is extremely without alcohol taste, and is concentrated into phase
It is 1.15 to density（60℃）, add customary adjuvant to make oral liquid.
2 tablet of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 15g；
The crude drug of recipe quantity is taken, plus 5 times are measured 70% alcohol reflux 2 times, every time 1.5 hours；United extraction liquid, filter
Cross, reclaim ethanol and concentrate；Concentrated solution drying under reduced pressure, is ground into fine powder, adds customary adjuvant, mixes；Dry-pressing is pelletized, tabletting,
Obtain final product.
3 capsule of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 60g；
Take the crude drug of recipe quantity, plus 10 times of amount methanol supersound extraction 3 times, first time 40min, the 2nd, 3 each 20min,
United extraction liquid, filtration, concentrating under reduced pressure；Concentrated solution drying under reduced pressure, is ground into fine powder, adds customary adjuvant, mixes；Dry-pressing system
Grain, loads capsule, obtains final product.
4 granule of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 120g；
The crude drug of recipe quantity is taken, 30min is soaked, is added 8 times of amount decoctings to boil three times, 1.5 hours every time, is filtered,
Merging filtrate, concentration；Concentrated solution by macroporous resin, first with 5 times of amount water elutions, abandon or adopt by eluent, then with adding 70% ethanol to wash
It is de-, eluent is collected, decompression recycling ethanol is to without alcohol taste；Less than 80 DEG C drying under reduced pressure, are ground into fine powder, add adjuvant, mix；
Dry-pressing is pelletized, and obtains final product.
5 oral liquid of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 90g；
Recipe quantity crude drug is taken, is added water to cook 2 times, 1.5 hours every time, collecting decoction, filtration, filtrate were concentrated, concentrated solution
Plus ethanol is stood to alcohol content to 80%, filtration, filtrate recycling ethanol is extremely without alcohol taste, and is concentrated into relative density for 1.15（60
℃）, adjuvant is added, oral liquid is made.
6 drop pill of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 9g；
The crude drug of recipe quantity is taken, 8 times of amounts water retting 6h, percolation 24h, flow velocity 2L/h are added.Percolate is collected, is centrifuged,
Upper macroporous adsorptive resins, first wash with water, then use 60% ethanol elution, collect ethanol elution, and filtrate concentration adds system
On medicine, acceptable adjuvant makes drop pill according to the routine techniquess of this area preparation.
7 tablet of embodiment
Prescription crude drug is constituted：Radix Et Rhizoma Rhei 30g, Tabanus 6g；
The crude drug of recipe quantity is taken, plus 5 times are measured 60% alcohol reflux 2 times, every time 1.5 hours；United extraction liquid, filter
Cross, reclaim ethanol and concentrate；Concentrated solution drying under reduced pressure, is ground into fine powder, adds customary adjuvant, mixes；Dry-pressing is pelletized, tabletting,
Obtain final product.
Embodiment 8
Prescription crude drug is constituted：Radix Et Rhizoma Rhei extract 30g, Tabanus extract 30g；
What the Radix Et Rhizoma Rhei extract, Tabanus extract respectively Radix Et Rhizoma Rhei, 60% alcohol reflux of Tabanus Jing were prepared carries
Take thing.Said extracted thing drying under reduced pressure is crushed for fine powder, mixed, add customary adjuvant to make granule.
Embodiment 9
Prescription raw material is constituted：Radix Et Rhizoma Rhei extract 30g, Tabanus extract 15g；
The Radix Et Rhizoma Rhei extract, Tabanus extract are respectively Radix Et Rhizoma Rhei, Tabanus Jing decoctings and boil the extract for preparing.Will be upper
Extract drying under reduced pressure is stated, is crushed as fine powder, mixed, add customary adjuvant to make tablet.
Embodiment 10
Prescription raw material is constituted：Radix Et Rhizoma Rhei extract 30g, Tabanus extract 60g；
The Radix Et Rhizoma Rhei extract, Tabanus extract are respectively Radix Et Rhizoma Rhei, Tabanus Jing acetone reflux and extract the extraction for preparing
Thing.Said extracted thing drying under reduced pressure is crushed for fine powder, mixed, add customary adjuvant to make capsule.
Embodiment 11
Prescription raw material is constituted：Radix Et Rhizoma Rhei extract 30g, Tabanus extract 90g；
The extraction that the Radix Et Rhizoma Rhei extract, Tabanus extract are respectively Radix Et Rhizoma Rhei, Tabanus Jing aqueous extraction-alcohol precipitation technologies are prepared
Thing, its alcohol precipitation concentration are the extract that 70% ethanol solution seepage pressure effects are obtained；By said extracted thing drying under reduced pressure, it is ground into thin
Powder, adds customary adjuvant, mixes；Dry-pressing is pelletized, and tabletting is obtained final product.
Claims (2)
1. a kind of Chinese medicine composition for treating cervical cancer, it is characterised in that raw material group of the Chinese medicine composition by following weight ratio
Into：
Radix Et Rhizoma Rhei water extract：Tabanus water extract=1：2.
2. application of the Chinese medicine composition as claimed in claim 1 in the medicine for preparing treatment cervical cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310100487.6A CN104069192B (en) | 2013-03-26 | 2013-03-26 | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310100487.6A CN104069192B (en) | 2013-03-26 | 2013-03-26 | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104069192A CN104069192A (en) | 2014-10-01 |
| CN104069192B true CN104069192B (en) | 2017-04-12 |
Family
ID=51591058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310100487.6A Active CN104069192B (en) | 2013-03-26 | 2013-03-26 | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104069192B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596943A (en) * | 2004-08-04 | 2005-03-23 | 韩淑云 | Leech capsule |
| CN102895395A (en) * | 2011-07-29 | 2013-01-30 | 苏州知微堂生物科技有限公司 | Preparation technology and production method for integrated new formulation of rhubarb and eupolnhagea pill |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101200419B1 (en) * | 2011-08-26 | 2012-11-14 | 대한민국 | Anti-diabetic composition comprising glycosaminoglycans derived from insect |
-
2013
- 2013-03-26 CN CN201310100487.6A patent/CN104069192B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596943A (en) * | 2004-08-04 | 2005-03-23 | 韩淑云 | Leech capsule |
| CN102895395A (en) * | 2011-07-29 | 2013-01-30 | 苏州知微堂生物科技有限公司 | Preparation technology and production method for integrated new formulation of rhubarb and eupolnhagea pill |
Non-Patent Citations (2)
| Title |
|---|
| 大黄蟅虫丸的临床新用途;梅全喜等;《中药材》;20011031;第24卷(第10期);第779-780页,尤其是第779页左栏第1段，第780页第13部分 * |
| 抵当汤抑制肿瘤转移的实验研究;王学良等;《湖南中医杂志》;20040531;第20卷(第3期);第69-70页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104069192A (en) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN103948689A (en) | Medicinal composition for treating non-small cell lung cancer and application thereof | |
| CN102008650A (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN101502579A (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN102362971B (en) | A kind of preparation method and preparation for the treatment of coronary heart disease Chinese medicine and effective chemical constituent thereof | |
| CN104013636A (en) | Anti-tumor pharmaceutical use of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN101537036A (en) | Soap pod saponin extract as well as preparation method and application thereof | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN101172143A (en) | Chinese traditional medicine compound, method for preparing the same and use thereof | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN104069192B (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN102697800B (en) | Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof | |
| CN101549032B (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug | |
| CN101371877B (en) | Qi tian dropping pill extract and Qi tian dropping pill as well as method for producing the same | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN101007047B (en) | An antitumor medicine composition and its preparation method | |
| CN101011543A (en) | Antineoplastic medicine composition | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN102139037A (en) | Application of rhizoma paridis total saponins in preparation of adjuvant drugs of anti-cancer drugs | |
| CN102416087A (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method as well as application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |